REG - OptiBiotix Health - Online distribution agreement - SlimBiome® Medical

OptiBiotix HealthAnnouncement

18/07/2019 07:00

RNS Number : 8881F
OptiBiotix Health PLC
18 July 2019
 


OptiBiotix Health plc
("OptiBiotix" or the "Company")
 
Online distribution agreement for SlimBiome® Medical
 
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces it has signed an agreement with BioEnergiser Ltd. ("BioEnergiser") for the online distribution of SlimBiome® Medical in the UK. SlimBiome® Medical is a CE marked medical device which independent clinical studies show reduces hunger, cravings for sweet and savoury foods, and fat intake. These functionalities help people who consume SlimBiome® Medical to modify the type and amount of food they eat, helping them to moderate their calorie intake and achieve sustainable weight loss.
 
The agreement grants BioEnergiser rights to distribute SlimBiome® Medical online within the UK whilst allowing OptiBiotix to continue to sell the product on its online store (Optibiotix.online). This agreement provides market exclusivity linked to minimum sales orders to be agreed after a review of sales, pricing, and future forecasts, six months after signing this agreement.
 
Founded in 1985, BioEnergiser is an established UK sales and marketing company specialising in consumer goods supplying retail, mail order, direct to TV and home shopping channels. BioEnergiser bring expertise in direct to consumer sales and marketing through mainstream digital and satellite TV and radio commercials, and advertising in national newspapers and magazines.  They have a track record of rapidly growing online sales with a recent product launch approaching £1.6m sales within the first year. Whilst there is no guarantee sales performance with other products can be replicated with SlimBiome® Medical we believe this demonstrates BioEnergisers experience in quickly building online sales in the healthcare market.  BioEnergiser's commitment to consumer marketing  is evidenced by their spend across their product range in print media alone of £5.1m in 2018. 
 
This agreement is a strategic step to take OptiBiotix's own label product (SlimBiome® Medical) direct to the UK consumer to enhance their online consumer health presence. This strategy helps build brand awareness, complementing any potential launch of products with major retailers, and creates demand for its functional ingredients (SlimBiome® and LPLDL®) in a wide range of products across the world.
 
 
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division commented: "We are pleased to announce this deal with BioEnergiser to distribute SlimBiome® Medical online in the UK. This is a significant and exciting step in accelerating the growth of OptiBiotix consumer health division. BioEnergiser's expertise in direct to consumer online sales and marketing will help build brand and consumer awareness of SlimBiome® Medical through TV and national newspaper advertising, complementing any potential future retail launch. The deal brings further value by providing us with economies of scale and will support revenue growth and profitability of OptiBiotix's prebiotics division going forward."
 
Steve Simmonds, Managing Director of BioEnergiser commented: "We are pleased to be working with OptiBiotix Health. The partnership brings together OptiBiotix's award winning CE marked SlimBiome® Medical with its IP portfolio and consumer and clinical studies, with BioEnergiser's sales and marketing expertise. We believe this to be a great fit and hope to be able to replicate the rapid sales growth we have seen with a number of recent product launches with SlimBiome® Medical."
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
For further information, please contact:
 
 



OptiBiotix Health plc


www.optibiotix.com




Stephen O'Hara, Chief Executive


Contact via Walbrook below














Cairn Financial Advisers LLP (NOMAD)








Liam Murray / Jo Turner / Ludovico Lazzaretti


Tel: 020 7213 0880




 
finnCap (Broker)








Geoff Nash / Kate Bannatyne (Corporate Finance)
 


 
Tel: 020 7220 0500




Camille Gochez (Corporate Broking)


 








 




goetzpartners securities Limited


Tel: 0203 859 7725




Ulrich Kinzel  


















Walbrook PR Ltd








Anna Dunphy


Mob: 07876 741 001








 
About OptiBiotix - www.optibiotix.com 
 
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
 
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
 
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRZMGMNKNFGLZM